Department of Translational Medicine, University of Ferrara, Via Aldo Moro 8, 44124, Ferrara, Italy.
Department of Cardiology, Arzignano General Hospital, Vincenza, Italy.
High Blood Press Cardiovasc Prev. 2023 May;30(3):227-233. doi: 10.1007/s40292-023-00574-5. Epub 2023 Apr 15.
Arterial Hypertension (HT) has been described as a common comorbidity and independent risk factor of short-term outcome in COVID-19 patients. However, data regarding the risk of new-onset HT during the post-acute phase of COVID-19 are scant.
We assess the risk of new-onset HT in COVID-19 survivors within one year from the index infection by a systematic review and meta-analysis of the available data.
Data were obtained searching MEDLINE and Scopus for all studies published at any time up to February 11, 2023, and reporting the long-term risk of new-onset HT in COVID-19 survivors. Risk data were pooled using the Mantel-Haenszel random effects models with Hazard ratio (HR) as the effect measure with 95% confidence interval (CI). Heterogeneity among studies was assessed using I statistic.
Overall, 19,293,346 patients (mean age 54.6 years, 54.6% males) were included in this analysis. Of them, 758,698 survived to COVID-19 infection. Over a mean follow-up of 6.8 months, new-onset HT occurred to 12.7 [95% CI 11.4-13.5] out of 1000 patients survived to COVID-19 infection compared to 8.17 [95% CI 7.34-8.53] out of 1000 control subjects. Pooled analysis revealed that recovered COVID-19 patients presented an increased risk of new-onset HT (HR 1.70, 95% CI 1.46-1.97, p < 0.0001, I = 78.9%) within seven months. This risk was directly influenced by age (p = 0.001), female sex (p = 0.03) and cancer (p < 0.0001) while an indirect association was observed using the follow-up length as moderator (p < 0.0001).
Our findings suggest that new-onset HT represents an important post-acute COVID-19 sequelae.
动脉高血压(HT)已被描述为 COVID-19 患者短期预后的常见合并症和独立危险因素。然而,关于 COVID-19 后急性阶段新发生 HT 的风险的数据很少。
我们通过对现有数据的系统回顾和荟萃分析,评估 COVID-19 幸存者在感染后一年内新发生 HT 的风险。
我们通过 MEDLINE 和 Scopus 检索了截至 2023 年 2 月 11 日随时发表的所有研究的数据,并报告了 COVID-19 幸存者中发生新的 HT 的长期风险。使用 Mantel-Haenszel 随机效应模型汇总风险数据,使用风险比(HR)作为效应量,95%置信区间(CI)。使用 I 统计量评估研究之间的异质性。
总体而言,纳入了 19293346 名患者(平均年龄 54.6 岁,54.6%为男性)。其中,758698 人存活至 COVID-19 感染。在平均 6.8 个月的随访中,与 1000 名对照患者相比,1000 名存活至 COVID-19 感染的患者中有 12.7 [95% CI 11.4-13.5]例发生新的 HT。汇总分析显示,COVID-19 康复患者在七个月内发生新的 HT 的风险增加(HR 1.70,95% CI 1.46-1.97,p<0.0001,I=78.9%)。该风险直接受年龄(p=0.001)、女性性别(p=0.03)和癌症(p<0.0001)的影响,而随访时间作为调节剂则存在间接关联(p<0.0001)。
我们的研究结果表明,新发生的 HT 是 COVID-19 后急性阶段的一个重要后遗症。